Eli Lilly (LLY.US) will appeal the UK's decision to reject its new Alzheimer's drug recommendation.

Zhtng Cijng APP learned that Eli Lilly (LLY.US) announced that it will appeal against the decision by the UK health authorities to reject the recommendation of its new Alzheimer's disease treatment drug Kisunla for inclusion in the country's public healthcare system on cost grounds.